FORM 10-QSB
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2007

                                       OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934

                            Commission File No: 09081

                                   CYBRDI INC.
                                   -----------
             (Exact name of registrant as specified in its charter)

CALIFORNIA                                               95-2461404
----------                                               ----------
(State or other jurisdiction of                          (I.R.S. Employer ID No)
incorporation or organization)

                      401 Rosemont Ave. Frederick, MD 21701
                      -------------------------------------
                     (Address of principal executive office)

                  Registrant's telephone number: (301) 644-3901

                                       N/A
               ---------------------------------------------------
               Former name, former address and former fiscal year,
                         (if changed since last report)

Indicate by a check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [ ] No [x]

Indicate by a check mark whether the registrant is an accelerated filer
(as defined in Rule 12b-2 of the Exchange Act). Yes [ ]     No [x]

Indicate by a check mark whether the registrant is a shell Company (as defined
by Rule 12b-2 of the Act). Yes [ ]     No [x]

                      APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of
Common Stock as of the latest practicable date:

50,456,569 shares of Common Stock, without par value, as of December 21, 2007


<PAGE>
                                      INDEX

                         PART I. - FINANCIAL INFORMATION

Item 1. Financial Statements

Consolidated Balance Sheets
  (Unaudited) as at September 30, 2007 and (Audited) December 31, 2006

Consolidated Statements of Operations
  (Unaudited) For the Three Months Ended September 30, 2007 and 2006;
  For The Nine Months Ended September 30, 2007 and 2006

Consolidated Statements of Cash Flow
  (Unaudited) For the Nine Months Ended September 30, 2007 and 2006

Notes to Consolidated Financial Statements (Unaudited)

Item 2. Management's Discussion and Analysis of Financial Condition and
        Results of Operation

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Item  4. Controls and Procedures

                          PART II. - OTHER INFORMATION

Item 1. Legal Proceedings

Item 2. Unregistered Sales of Equity Securities

Item 3. Defaults upon senior securities

Item 4. Submission of matters to a vote of security holders

Item 5. Exhibits

                                       1
<PAGE>
                           FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-QSB for the quarterly period ended September
30, 2007 contains "forward-looking statements". Generally, the words "believes",
"anticipates," "may," "will," "should," "expect," "intend," "estimate,"
"continue," and similar expressions or the negative thereof or comparable
terminology are intended to identify forward-looking statements which include,
but are not limited to, statements concerning our expectations regarding our
working capital requirements, financing requirements, business prospects, and
other statements of expectations, beliefs, future plans and strategies,
anticipated events or trends, and similar expressions concerning matters that
are not historical facts. Such statements are subject to certain risks and
uncertainties, including the matters set forth in this Quarterly Report or other
reports or documents we file with the Securities and Exchange Commission from
time to time, which could cause actual results or outcomes to differ materially
from those projected. Undue reliance should not be placed on these
forward-looking statements which speak only as of the date hereof. We undertake
no obligation to update these forward-looking statements. In addition, the
forward-looking statements in this Quarterly Report on Form 10-QSB involve known
and unknown risks, uncertainties and other factors that could cause the actual
results, performance or achievements of us to differ materially from those
expressed in or implied by the forward-looking statements contained herein.

                                       2
<PAGE>

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CYBRDI, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
                                                                  SEPTEMBER 30,2007  DECEMBER 31,2006
                                                                  -----------------  ----------------
                                                                      (UNAUDITED)       (AUDITED)
<S>                                                                   <C>              <C>
                                  ASSETS
CURRENT ASSETS
     Cash and equivalents                                             $   744,821      $   782,899
     Accounts receivable                                                   28,050           37,382
     Inventories                                                          374,096          366,161
     Loan to unaffiliated company                                       1,107,730        3,241,886
     Other receivables and prepaid expenses                               124,567          200,384
                                                                      -----------      -----------
TOTAL CURRENT ASSETS                                                    2,379,264        4,628,712
PROPERTY, PLANT AND EQUIPMENT, NET                                        494,265          505,714
CONSTRUCTION IN PROGRESS                                                   37,525               --
INTANGIBLE ASSETS, NET                                                  3,600,391          519,415
                                                                      -----------      -----------

TOTAL ASSETS                                                            6,511,445        5,653,841
                                                                      ===========      ===========

                   LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
     Accounts payable and accrued expenses                                158,628          133,463
     Other payables                                                        36,256           31,508
     Loan from affiliated company                                         266,923               --
     Amount due to stockholders/officers                                  258,454          205,218
                                                                      -----------      -----------
TOTAL CURRENT LIABILITIES                                                 720,261          370,189

MINORITY INTERESTS                                                      1,518,115        1,124,557
                                                                      -----------      -----------

TOTAL LIABILITIES                                                       2,238,376        1,494,746
                                                                      -----------      -----------

STOCKHOLDERS' EQUITY
     Preferred Stock, $1.00 per value, 500,000 shares authorized,
             zero shares issued and outstanding                                --               --
     Common Stock, no par value, 150,000,000 shares authorized,
             50,456,569 shares issued and outstanding                          --               --
     Additional paid-in capital                                         3,571,864        3,601,932
     Reserve funds                                                        336,885          336,885
     Accumulated deficit                                                 (106,010)         (12,639)
     Accumulated other comprehensive income                               470,330          232,917
                                                                      -----------      -----------
TOTAL STOCKHOLDERS' EQUITY                                              4,273,069        4,159,095
                                                                      -----------      -----------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                            $ 6,511,445      $ 5,653,841
                                                                      ===========      ===========
</TABLE>

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       3
<PAGE>

CYBRDI, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
<TABLE>
<CAPTION>
                                                  THREE MONTHS ENDED   THREE MONTHS ENDED    NINE MONTHS ENDED    NINE MONTHS ENDED
                                                  SEPTEMBER 30, 2007   SEPTEMBER 30, 2006    SEPTEMBER 30, 2007   SEPTEMBER 30, 2006
                                                  ------------------   ------------------    ------------------   ------------------
                                                      (Unaudited)          (Unaudited)           (Unaudited)         (Unaudited)
<S>                                                  <C>                  <C>                  <C>                  <C>
REVENUE
      Products                                       $    178,649         $    118,063         $    496,370         $    291,651
      Service rendered                                      8,333               30,740               47,171               84,611
                                                     ------------         ------------         ------------         ------------
         TOTAL REVENUE                                    186,982              148,803              543,541              376,262
                                                     ------------         ------------         ------------         ------------
COST OF SALES
      Products                                             98,348               48,292              229,942              138,837
      Service rendered                                         --               (1,763)               3,962                3,417
                                                     ------------         ------------         ------------         ------------
        TOTAL COST OF SALES                                98,348               46,529              233,904              142,254
                                                     ------------         ------------         ------------         ------------
GROSS PROFIT                                               88,634              102,274              309,637              234,008
                                                     ------------         ------------         ------------         ------------

OPERATING EXPENSES:
      Selling and distribution expenses                    29,055               25,863               88,332               84,510
      General and administrative expenses                 192,934              138,797              470,032              457,560
                                                     ------------         ------------         ------------         ------------
TOTAL OPERATING EXPENSES                                  221,989              164,660              558,364              542,070
                                                     ------------         ------------         ------------         ------------

LOSS FROM OPERATIONS                                     (133,355)             (62,386)            (248,727)            (308,062)
                                                     ------------         ------------         ------------         ------------

OTHER INCOME/(EXPENSE)
      Interest income, net                                 16,419               64,745               94,261              195,696
      Other income, net                                     1,729                3,187               70,264               10,663
                                                     ------------         ------------         ------------         ------------
TOTAL OTHER INCOME                                         18,148               67,932              164,525              206,359
                                                     ------------         ------------         ------------         ------------

(LOSS) INCOME BEFORE INCOME TAXES                        (115,207)               5,546              (84,202)            (101,703)
Income Taxes Expenses                                          --                   --                   --                   --
                                                     ------------         ------------         ------------         ------------
(Loss) Income before Minority Interest                   (115,207)               5,546              (84,202)            (101,703)

Minority Interest                                          (9,208)              (1,509)               9,171               (5,259)
                                                     ------------         ------------         ------------         ------------
NET (LOSS) INCOME                                    $   (105,999)        $      7,055         $    (93,373)        $    (96,444)
                                                     ============         ============         ============         ------------

Other Comprehensive Income:
Foreign Currency Translation gain                         143,886               41,896              237,413               76,524
                                                     ------------         ------------         ------------         ------------
COMPREHENSIVE INCOME (LOSS)                          $     37,887         $     48,951         $    144,040         $    (19,920)
                                                     ============         ============         ============         ============

Net (Loss) Income Per Common Share
      Basic and Diluted                              $      (0.00)        $       0.00         $      (0.00)        $      (0.00)
                                                     ============         ============         ============         ============

Weighted Average Number of Shares Outstanding
      Basic and Diluted                                50,456,569           50,456,569           50,456,569           50,456,569
                                                     ============         ============         ============         ============
</TABLE>

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       4
<PAGE>

CYBRDI INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
<TABLE>
<CAPTION>
                                                                       FOR NINE MONTHS ENDED    FOR NINE MONTHS ENDED
                                                                         SEPTEMBER 30, 2007       SEPTEMBER 30, 2006
                                                                       ---------------------    ---------------------
                                                                             (UNAUDITED)             (UNAUDITED)
<S>                                                                          <C>                     <C>
CASH FLOWS FROM OPERATING ACTIVITIES
     NET LOSS                                                                $   (93,373)            $   (96,444)
     ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH
       PROVIDED BY OPERATING ACTIVITIES:
         Depreciation and amortization                                           125,350                 154,315
         Loss on disposal of fixed assets                                          4,142                      --
         Minority interest                                                         9,171                  (5,259)
     CHANGES IN OPERATING ASSETS AND LIABILITIES:
         Accounts receivable                                                      10,451                 355,037
         Inventories                                                               6,987                 (48,404)
         Other receivable and prepaid expenses                                    80,786                (151,566)
         Accounts payable and accrued expenses                                    18,837                  37,184
         Other payables                                                            3,302                  19,378
                                                                             -----------             -----------
     NET CASH PROVIDED BY OPERATING ACTIVITIES                                   165,653                 264,241
                                                                             -----------             -----------

CASH FLOWS FROM INVESTING ACTIVITIES
         Purchases of property, plant and equipment                              (36,353)                (42,637)
         Payment for construction in progress                                    (37,525)                     --
         Purchases intangible assets                                          (3,123,458)                     --
         Proceeds from property disposal                                             395                      --
         Proceeds from loan to affiliated company                                266,923                      --
         Proceeds from (payment for) loan to unaffiliated company              2,178,343              (3,200,911)
                                                                             -----------             -----------
     NET CASH USED IN INVESTING ACTIVITIES                                      (751,675)             (3,243,548)
                                                                             -----------             -----------

CASH FLOWS FROM FINANCING ACTIVITIES
         Proceeds from minority shareholders contribution                        354,319                      --
         Proceeds from shareholders/officers                                     257,473                   1,000
         Payment to shareholders/officers                                       (188,038)               (411,655)
                                                                             -----------             -----------
     NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES                         423,754                (410,655)
                                                                             -----------             -----------

NET DECREASE IN CASH AND EQUIVALENTS
     Net Decrease in Cash and Equivalents                                       (162,268)             (3,389,962)
     Effect of Exchange Rate Changes on Cash and Equivalents                     124,190                  42,876
     Cash and Equivalents, at Beginning of Period                                782,899               4,206,695
                                                                             -----------             -----------

     CASH AND EQUIVALENTS, AT END OF PERIOD                                  $   744,821             $   859,609
                                                                             ===========             ===========
</TABLE>

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       5
<PAGE>

CYBRDI, INC. AND SUBSIDIDARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A - BASIS OF PRESENTATION

1. INTERIM FINANCIAL STATEMENTS

The unaudited consolidated financial statements of Cybrdi Inc. and subsidiary
have been prepared in accordance with U.S. generally accepted accounting
principles for interim financial information and pursuant to the requirements
for reporting on Form 10-QSB. Accordingly, they do not include all the
information and footnotes required by accounting principles generally accepted
in the United States of America for annual financial statements. However, the
information included in these interim financial statements reflects all
adjustments (consisting solely of normal recurring adjustments) which are, in
the opinion of management, necessary for the fair presentation of the
consolidated financial position and the consolidated results of operations.
Results shown for interim periods are not necessarily indicative of the results
to be obtained for a full year. The consolidated balance sheet information as of
December 31, 2006 was derived from the audited consolidated financial statements
included in our Annual Report on Form 10-KSB. These interim financial statements
should be read in conjunction with that report.

The consolidated financial statements include the accounts of Cybrdi, Inc. and
its wholly-owned subsidiaries and joint ventures. All material intercompany
balances and transactions have been eliminated.

2. DESCRIPTION OF BUSINESS

Cybrdi, Inc. (f/k/a Certron Corporation) was incorporated on August 1, 1966,
under the laws of the State of California. Until approximately June 2004, our
business consisted primarily of the distribution of magnetic media products,
primarily blank audio and video cassettes. Due to continuing intense price
competition and technological changes in the marketplace for our products, we
lost our remaining significant customers and disposed of , or wrote off our
remaining inventory. As a result of these occurrences, we concluded that our
audio and videotape businesses were no longer viable and some of our product
lines were obsolete and we placed our emphasis on attempting to find a buyer.

In November 2004, we formed a wholly-owned subsidiary , Certron Acquisition
Corp., a Maryland corporation ("Acquisition Sub") to acquire all of the
ownership interests in Cybrdi, Inc., a privately held company incorporated in
the State of Maryland ("Cybrdi Maryland"). We acquired Cybrdi Maryland in
exchange for 47,328,263 shares of our common stock in a merger transaction. As a
result of the merger, the former shareholders of Cybrdi Maryland acquired
approximately 93.8% of the outstanding shares of our common stock. As a result
of the ownership interests of the former shareholders of Cybrdi Maryland, for
financial statement reporting purposes, the transaction was treated as a reverse
acquisition, with Cybrdi Maryland deemed the accounting acquirer and Certron
Corporation deemed the accounting acquiree. Historical information of the
surviving company is that of Cybrdi Maryland.

Cybrdi Maryland was established in 2001 to acquire an interest in biogenetic
products commercialization and related services entities in Asia. On March 5,
2003, Cybrdi Maryland acquired an 80% interest in Shaanxi Chao Ying
Biotechnology Co., Ltd. ("Chaoying Biotech"), a sino-foreign equity joint
venture established in July 2000 in the People's Republic of China ("PRC"),
through the exchange of 99% of its shares to the existing shareholders of
Chaoying Biotech. For financial statement reporting purposes, the merger was
treated as a reverse acquisition, with Chaoying Biotech deemed the accounting
acquirer and Cybrdi Maryland deemed the accounting acquiree.

Chaoying Biotech is a sino-foreign equity joint venture between Shaanxi Chao
Ying Personal Care Group Ltd. (the "Chinese Partner", a PRC corporation) and
Immuno-OncoGenomics Inc. (the "Foreign Partner", a U.S. corporation). The joint
venture agreement has a 15 year operating period starting from its formation in
July 2000 and it may be extended upon mutual consent. The principal activities
of Chaoying Biotech are research, manufacture and sale of various high-quality
tissue arrays and the related services in the PRC.


                                       6
<PAGE>

Most of our activities are conducted through Chaoying Biotech. Chaoying Biotech,
with its principal operations located in China, aims to take advantage of
China's cientific talent, low wage rates, less stringent biogenetic regulation,
and large genetic population as it introduces its growing list of tissue micro
array products.

On February 10, 2005, we completed the merger with Cybrdi Maryland and changed
its name to Cybrdi, Inc.

On July 26, 2007, Chaoying Biotech entered into an acquisition agreement with
Shaanxi Chaoying Personal Care Group Co., Inc. its Chinese partner, which is a
principal shareholder of the Company . Mr. Bai, our chief executive officer and
a director is also a principal of our Chinese partner On July 28, 2007, Chaoying
Biotech invested RMB15 millions (equivalent to US $1,983,078) to acquire an
83.33% equity ownership of Shandong Chaoying Culture and Entertainment Co., Ltd
("SD Chaoying") from its Chinese partner. SD Chaoying is a corporation organized
in Shandong provice P.R.China. On September 5, 2007, Shandong Commercial
government had approved this acquisition and the ownership title of SD Chaoying
had been transferred to Chaoying Biotech from its Chinese partner. The future
business of SD Chaoying will primarily be focused on culture and entertainment,
including spa activities , cosmetic and personal care, body building, gambling,
catering, and lodging SD Chaoying will have a specific emphasis on casino
gambling, which has been approved by Shandong Administration for Civil Affairs.
As of September 30, 2007, SD Chaoying is still in the development stage and
there is no actual business. The development and construction of the facility is
anticipated to be completed in December 2008.

On March 10 , 2007 we entered into a Sales Agency Agreement with BioMax , Ltd.,
a U.S. reseller and we terminated our branch office to reduce the general and
administrative costs of Cybrdi Maryland in October 2007.

3. USE OF ESTIMATES:

The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ materially from those
estimates.

4. REVENUE RECOGNITION

Revenue represents the invoiced value of goods sold recognized upon the delivery
of goods to customers and service income is recognized when services are
provided. Deferred revenue represents the undelivered portion of invoiced value
of goods sold to customers. Sales transactions not meeting all the conditions of
the full accrual method are accounted for using the deposit method of
accounting. Under the deposit method, all costs are capitalized as incurred, and
payments received from the buyer are recorded as customer deposits.

5. REVERSE MERGER

On February 10, 2005, (the "Closing Date") we closed on an Agreement and Plan of
Merger (the "Agreement") among Certron Corporation ("Certron"), a California
corporation, Certron Acquisition Corp., a Maryland corporation and a
wholly-owned subsidiary of Certron ("Acquisition Sub"), and Cybrdi, Inc., a
Maryland corporation ("Cybrdi - Maryland") relating to the acquisition by
Certron of all of the issued and outstanding capital stock of Cybrdi -Maryland
in exchange for shares of common stock of Certron that aggregated approximately
93.8% of the issued and outstanding common stock of Certron. Pursuant to the
terms of the Agreement, at the Closing Date (a) Acquisition Sub has been merged
with and into Cybrdi - Maryland, with Cybrdi - Maryland being the surviving
corporation, (b) the common stock of Cybrdi-Maryland has been cancelled and
converted into the right to receive shares of the common stock of Certron at an
exchange ratio of 1.566641609 per share. This resulted in the issuance of
47,328,263 shares of the Certron's common stock, and (c) each share of the
common stock of Acquisition Sub has been converted in to and become one share of
the common stock of Cybrdi-Maryland. The share exchange has been accounted for
as a reverse merger under the purchase method of accounting. Accordingly, Cybrdi


                                       7
<PAGE>

Inc. will be treated as the continuing entity for accounting purposes and the
historical financial statements presented will be those of Cybrdi, Inc.

In connection with the Agreement, on February 10, 2005, we amended our articles
of incorporation to authorize the issuance of 150 million shares of common stock
no par value and 500,000 shares of preferred stock, $1.00 par value per share,
none of which are issued or outstanding.

Concurrent with the filing of the Articles of Merger, all of our then existing
officers and directors tendered their resignation and Yanbiao Bai was appointed
as our Chairman of the Board of Directors. Mr. Bai then nominated the balance of
the Board of Directors.

On June 30, 2005 our Board of Directors changed our fiscal year end from October
31 to December 31.

6. GOVERNMENT GRANT

In 2000, the P.R. China Government launched the "Western Development Project"
which included the development of 15 specifically named technologies and has
allocated government grants to encourage the development of these technologies.
For the nine months ended September 30, 2007 and 2006, we received $59,903 and
$0 for the government grants under the Western Development Project,
respectively.

7. RECENT ACCOUNTING PRONOUNCEMENTS

In September 2006, the Financial Accounting Standard Board ("FASB") issued SFAS
No. 157, "Fair Value Measurements," which provides enhanced guidance for using
fair value to measure assets and liabilities. SFAS No. 157 provides a common
definition of fair value and establishes a framework to make the measurement of
fair value in generally accepted accounting principles more consistent and
comparable. SFAS No. 157 also requires expanded disclosures to provide
information about the extent to which fair value is used to measure assets and
liabilities, the methods and assumptions used to measure fair value, and the
effect of fair value measures on earnings. SFAS No. 157 is effective for
financial statements issued in fiscal years beginning after November 15, 2007
and to interim periods within those fiscal years. We are currently in the
process of evaluating the effect, if any, the adoption of SFAS No. 157 will have
on our consolidated results of operations, financial position, or cash flows.

In September 2006, the Securities and Exchange Commission issued Staff
Accounting Bulletin ("SAB") No. 108, "Considering the Effects of Prior Year
Misstatements when Quantifying Misstatements in Current Year Financial
Statements". SAB No. 108 was issued in order to eliminate the diversity in
practice surrounding how public companies quantify financial statement
misstatements. SAB No. 108 requires that registrants quantify errors using both
a balance sheet (iron curtain) approach and an income statement (rollover)
approach, then evaluate whether either approach results in a misstated amount
that, when all relevant quantitative and qualitative factors are considered, is
material. SAB No. 108 is effective for fiscal years ending after November 15,
2006. We adopted the bulletin during 2006. The adoption did not have a material
effect on the consolidated results of operations, financial position, or cash
flows.

In July 2006, the FASB issued FASB Interpretation No. 48, "Accounting for
Uncertainty in Income Taxes an Interpretation of FASB Statement No. 109" ("FIN
48"). FIN 48 clarifies the accounting for uncertainty in income taxes recognized
in a company's financial statements in accordance with FAS 109, "Accounting for
Income Taxes". FIN 48 prescribes a recognition threshold and measurement
attribute for the financial statement recognition and measurement of a tax
position taken or expected to be taken in a tax return. FIN 48 also provides
guidance on derecognizing, classification, interest and penalties, accounting in
interim periods, disclosure and transition. The requirements of FIN 48 are
effective beginning January 1, 2007.

                                       8
<PAGE>

NOTE B - ASSETS

The September 30, 2007 balance sheet included total current assets of $2,379,264
and non-current assets of $4,132,181 of these amounts, approximately $744,821 in
cash and $28,050 in accounts receivable are planned for funding current
operations and for future business expansion.

Other current assets also included inventories, loan to unaffiliated company,
and other receivable and prepaid expenses. Inventories are primarily finished
goods and a minimal amount of raw materials, work in process, packaging
material. Inventories are stated at the lower of cost or market. Cost of raw
materials is determined on the basis of first in first out method ("FIFO").
Finished goods are determined on the weighted average basis and are comprised of
direct materials, direct labor and an appropriate proportion of overhead.

The other primary assets included in current assets are loan to unaffiliated
company.

Loan to unaffiliated company consists of loans to QuanYe Security Co.,Ltd
("QuanYe") , an unrelated PRC registered company located in Xian PRC. QuanYe is
engaged in the pawnshop business and their primary business is offering
alternative financing to small local companies. According to the loan agreement,
QuanYe has received loans from Chaoying Biotech of a total amount of
RMB29.3Million (equivalent to $3,849,185) since January 2006. As of September
30, 2007, the loan balance had been reduced to RMB8.3 Million (equivalent to
$1,107,730). The interest rate for these loans initially was 8% per year, and
drop down to 5% since October 9, 2006.

Management believes and views QuanYe as an alternative financial institution and
believes it is an efficient way to use its cash on hand. The regular market
interest rate in the PRC is 0.72% per annum. Cybrdi expects to obtain higher
interest income for its unused funds through these types of loan arrangements.
However, these advances are unsecured and have a default risk higher than a bank
deposit.

Included in-non-current assets are property, plant and equipment, construction
in progress and intangible assets.. Property, plant and equipment mainly consist
of building, motor vehicles, leasehold improvement, software-website, and
machinery used for product manufacturing located in the People's Republic of
China ("PRC"), and office equipment located in PRC and United States.
Depreciation on property, plant and equipment is computed using the straight
-line method over the estimated useful life of the assets. The majority of the
assets have estimated useful lives of 10 years. Building and office equipments
have estimated useful lives of 20 and 5 years, respectively. Construction in
process of $37,525 mainly consists of a development and construction of a casino
in Shandong Provice, which will be transferred to fixed assets in SD Chaoying
when it is finished. Intangible assets include a tissue chip patent and land use
right. Effective January 1, 2002, with the adoption of SFAS No. 142, intangible
assets with a definite life are amortized on a straight-line basis. The patent
is being amortized over its estimated life of 10 years. As of September 30,
2007, SD Chaoying is still in the development stage, accordingly, its land use
rights will be amortized over its estimated useful life of either 40 or 70
years, as applicable, in accordance with applicable Chinese law.

NOTE C - LIABILITIES

As of September 30, 2007, the balance sheet included total liabilities of
$2,238,376 of which $1,518,115 represents the 20% minority interest in Chaoying
Biotech and 16.67% minority interest in SD Chaoying. Included in the total
liabilities $258,454 was due to stockholders who are also our officers. The
amounts are mainly an advance to assist with our operations. This advance is
non-interest bearing and has no set repayment terms. And included in the total
libilities $266,923 was a loan from an affiliated company, Shaanxi Chaoying
Personal Care Group Co.,Inc, located in Shaanxi province P.R.China, this loan is
also non-interest bearing and has no set repayment terms.

In accordance with the relevant tax laws and regulations of the PRC, Chaoying
Biotech is entitled to full exemption from Corporation Income Tax ("CIT") for
the first two years and a 50% reduction in CIT for the next three years,
commencing from the first profitable year after offsetting all tax losses
carried forward from the previous five years. As 2003 was Chaoying Biotech's
first profitable year, we began to record 50% CIT provision for the first
quarter of 2005. The effective tax rate is approximately 7.5%. Since there is no


                                       9
<PAGE>

taxable income after offsetting all tax losses carried forward, no income taxes
were required as of September 30, 2007 and 2006, respectively.

NOTE D - STOCKHOLDERS' EQUITY

As a result of the reverse merger (see Note A), the common stock of
Cybrdi-Maryland has been cancelled and converted into shares of common stock of
Certron at an exchange ratio of 1.566641609 per share. This resulted in the
issuance of 47,328,263 shares of Certron's common stock to the Cybrdi
shareholders. As of September 30, 2007, we had 50,456,569 shares of common stock
issued and outstanding. Historical information of the surviving company is that
of Cybrdi - Maryland.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
        RESULTS OF OPERATION

The following discussion and analysis should be read in conjunction with our
Financial Statements and Notes thereto appearing elsewhere in this Report on
Form 10-QSB as well as our other SEC filings.

PLAN OF OPERATIONS

We focus on biogenetics commercialization and healthcare product applications.
Our primary business includes sales of tissue microarray products and services.
Tissue chips, also called microtissue arrays, provide high-throughput molecular
profiling and parallel analysis of biological and molecular characteristics for
hundreds of pathologically controlled tissue specimens. Tissue arrays can
provide rapid and cost-effective localization and evaluation of proteins, RNA,
or DNA molecules, which are particularly useful for functioning genomic studies.
Cybrdi manufactures both human and animal tissue microarray for a wide variety
of scientific uses, including drug discovery and development purposes.

Our business strategy and focus in the near future include

     o   Enhancing R&D in TMAs and technical service
     o   Expanding our product portfolio and virtual tissue array data bank
         (vTMAB)
     o   Launch the health diagnosis kit for obesity and skin disease
     o   Participate in the culture and entertainment field

With our sophisticated research in genes, we can provide the professional health
diagnostic service for our customers. We can check the reasons for obesity and
other skin diseases like freckles by our genetic analysis, which offers more
accurate and specialized diagnosis than other similar services in the current
market. Such information can be utilized to guide customers to set up the right
health or fitness program. At present, we provide genetic tests for the
mechanism of obesity or skin disease.

We will also explore other business development opportunities that can leverage
our sales platform and relationship with affiliated companies. Until such time
as we can identify attractive marketing opportunities, we will loan available
cash on a short term unsecured basis to non-affiliated third parties in order to
generate interest income.

Commencing from the third quarter of year 2007, we had developed a new gene
detective tissue array, called New Kits, and started to offer them to our
customers.

On July 28, 2007, we acquired an 83.33% equity ownership of SD Chaoying from our
Chinese partner, which will be primarily engaged in developing and operating
culture and entertainment business after 2008, which will consist primarily of a
spa activities, cosmetic personal care, hotel, and casino. Our Chinese partner
is a principal shareholder of the Company and Mr. Bai, our chief executive
officer and a director is also a principal of our Chinese partner. Commencing in
September 2007, SD Chaoying began constructing the facility. The total useful
land and net building area for the project consists of approximately 50,000 and
33,000 square meters, respectively of which 52% will constitute property for
business use and 48% for residential use. The construction is anticipated to be
completed in December 2008. SD Chaoying intends to focus on spa activities,


                                       10
<PAGE>

cosmetic personal care, hotel, and casino gambling, which has been approved by
Shandong Administration for Civil Affairs.

RESULTS OF OPERATIONS

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2007
COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2006

<TABLE>
<CAPTION>
                                           FOR THREE MONTHS            FOR THREE MONTHS                    2007 VS 2006
                                           ENDED SEPTEMBER 30, 2007    ENDED SEPTEMBER 30, 2006     INCREASE/ (DECREASE)
                                           ------------------------    ------------------------     --------------------
                                                  A                           B                            C=A-B           D=C/B
<S>                                                 <C>         <C>             <C>         <C>                <C>             <C>
REVENUE
      Products                                      $ 178,649    96%            $ 118,063    79%               $ 60,586          51%
      Service rendered                                  8,333    4%                30,740    21%                (22,407)        -73%
                                           -------------------         -------------------          --------------------
         TOTAL REVENUE                                186,982   100%              148,803   100%                 38,179          26%
                                           -------------------         -------------------          --------------------
COST OF SALES
      Products                                         98,348    55%               48,292    41%                 50,056         104%
      Service rendered                                      -    0%                (1,763)   -6%                  1,763        -100%
                                           -------------------         -------------------          --------------------
        TOTAL COST OF SALES                            98,348    53%               46,529    31%                 51,819         111%
                                           -------------------         -------------------          --------------------
GROSS PROFIT                                           88,634    47%              102,274    69%                (13,640)        -13%
                                           -------------------         -------------------          --------------------

OPERATING EXPENSES:
      Selling and distribution expenses                29,055                      25,863                         3,192          12%
      General and administrative expenses             192,934                     138,797                        54,137          39%
                                           -------------------         -------------------          --------------------
TOTAL OPERATING EXPENSES                              221,989   119%              164,660   111%                 57,329          35%
                                           -------------------         -------------------          --------------------

(LOSS) INCOME FROM OPERATIONS                        (133,355)  -71%              (62,386)  -42%                (70,969)        114%
                                           -------------------         -------------------          --------------------
OTHER INCOME/(EXPENSE)
      Interest income                                  16,419                      64,745                       (48,326)        -75%
      Other income, net                                 1,729                       3,187                        (1,458)        -46%
                                           -------------------         -------------------          --------------------
TOTAL OTHER INCOME                                     18,148    10%               67,932    46%                (49,784)        -73%
                                           -------------------         -------------------          --------------------

(LOSS) INCOME BEFORE INCOME TAXES                    (115,207)                      5,546                      (120,753)      -2177%
Income Taxes Expenses                                       -                           -                             -
                                           -------------------         -------------------          --------------------
(Loss) Income before Minority Interest               (115,207)  -62%                5,546    4%                (120,753)      -2177%
Minority (Loss)/Interest                               (9,208)   -5%               (1,509)   -1%                 (7,699)        510%
                                           -------------------         -------------------          --------------------

NET (LOSS) INCOME                                  $ (105,999)  -57%             $ 7,055     5%              $ (113,054)      -1603%
                                           ===================         ===================          ====================
</TABLE>

NET SALES

We generate three categories of revenues: tissue chip & kit product and
services. The net sales increased $38,179 to $186,982 for the three months ended
September 30, 2007 from $148,803 for the three months ended September 30, 2006.

Tissue Chip & Kit Product: The net sales increased $60,586 to $178,649 for the
three months ended September 30, 2007 as compared to $118,063 for the three
months ended September 30, 2006. The primary reason for the increase was due to
the sale of higher unit price tissue chip products in the third quarter of 2007
as compared to the products sold in the third quarter of 2006. The products
sales in third quarter of 2007 also contained the new product kits which
generated net sales revenue of $4,066 in third quarter of 2007.

                                       11
<PAGE>

Services: Fewer technical service orders were received during the three months
of 2007 as compared to 2006 resulting in a decrease in sales of $22,407 to
$8,333 from $30,740 for the three months ended September 30, 2007 as compared to
September 30, 2006. This decline is primarily attributable to increased
competition from larger better financed multinationals that can compete on the
basis of name recognition and pricing.

GROSS MARGIN

Gross margin as a percentage of sales decreased to 47% for the three months
ended September 30, 2007 from 69% for three months ended September 30, 2006.
Gross profit for the three months ended September 30, 2007 decreased $13,640 to
$88,634 from $102,274 for the three months ended September 30, 2006. The primary
reason for the decrease was we sold the tissue chip products with lower
individual gross margins in third quarter 2007 as compared to the products sold
in the third quarter of 2006.

OPERATING EXPENSES

Our operating expenses increased $57,329 to $221,989 for the three months ended
September 30, 2007 from $164,660 for the three months ended September 30, 2006.
This is primarily due to an increase in general and administrative expenses of
$54,137 to $192,934 for the three months ended September 30, 2007 from $138,797
for the three months ended September 30, 2006, and an increase in selling and
distribution expenses of $3,192 to $29,055 for the three months ended September
30, 2007 from $25,863 for the three months ended September 30, 2006. The
increase in general and administrative expenses were primarily attributable to
the increases of salaries and payroll taxes in Cybrdi Maryland, the increased
R&D charges in Chaoying Biotech, and the start-up costs for newly acquired
subsidiary, SD Chaoying.

OTHER INCOME

Interest income decreased by $48,326 to $16,419 for the three months ended
September 30, 2007 from $64,745 for the three months ended September 30, 2006.
The interest income is primarily attributable to loans which we have made to
QuanYe. The decrease in interest income was primarily attributable to the
repayment by QuanYe in the amount of $2,178,343 loan during the first three
quarters of year 2007.

INCOME TAXES

We have not recorded a provision for federal income tax for the third quarter
ended September 30, 2007 and 2006, due to no taxable income after offsetting all
taxes losses carried forward from prior periods. In accordance with the relevant
tax laws and regulations of the People's Republic of China, Chaoying Biotech is
entitled to full exemption from Corporation Income Tax ("CIT") for the first two
years and a 50% reduction in CIT for the next three years, commencing from the
first profitable year after offsetting all tax losses carried forward from the
previous five years. As 2003 was Chaoying Biotech's first profitable year, we
begin to record 50% CIT provision from the first quarter of 2005. The effective
income tax rate is 7.5% for the quarter ended September 30, 2007 and 2006.

                                       12
<PAGE>

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007
COMPARED TO NINE MONTHS ENDED JUNE 30, 2006

<TABLE>
<CAPTION>
                                          FOR NINE MONTHS             FOR NINE MONTHS                     2007 VS 2006
                                          ENDED SEPTEMBER 30, 2007    ENDED SEPTEMBER 30, 2006     INCREASE/ (DECREASE)
                                          ------------------------    ------------------------     --------------------
                                                 A                           B                            C=A-B           D=C/B
<S>                                                <C>         <C>             <C>        <C>                <C>             <C>
REVENUE
      Products                                     $ 496,370    91%            $ 291,651    78%              $ 204,719          70%
      Service rendered                                47,171    9%                84,611    22%                (37,440)        -44%
                                          -------------------         -------------------          --------------------
         TOTAL REVENUE                               543,541   100%              376,262   100%                167,279          44%
                                          -------------------         -------------------          --------------------
COST OF SALES
      Products                                       229,942    46%              138,837    48%                 91,105          66%
      Service rendered                                 3,962    8%                 3,417    4%                     545          16%
                                          -------------------         -------------------          --------------------
        TOTAL COST OF SALES                          233,904    43%              142,254    38%                 91,650          64%
                                          -------------------         -------------------          --------------------
GROSS PROFIT                                         309,637    57%              234,008    62%                 75,629          32%
                                          -------------------         -------------------          --------------------

OPERATING EXPENSES:
      Selling and distribution expenses               88,332                      84,510                         3,822           5%
      General and administrative expenses            470,032                     457,560                        12,472           3%
                                          -------------------         -------------------          --------------------
TOTAL OPERATING EXPENSES                             558,364   103%              542,070   144%                 16,294           3%
                                          -------------------         -------------------          --------------------

LOSS FROM OPERATIONS                                (248,727)  -46%             (308,062)  -82%                 59,335         -19%
                                          -------------------         -------------------          --------------------
OTHER INCOME/(EXPENSE)
      Interest income                                 94,261                     195,696                      (101,435)        -52%
      Other income, net                               70,264                      10,663                        59,601         559%
                                          -------------------         -------------------          --------------------
TOTAL OTHER INCOME                                   164,525    30%              206,359    55%                (41,834)        -20%
                                          -------------------         -------------------          --------------------

INCOME (LOSS) BEFORE INCOME TAXES                    (84,202)                   (101,703)                       17,501         -17%
Income Taxes Expenses                                      -                           -                             -
                                          -------------------         -------------------          --------------------
(Loss) Income before Minority Interest               (84,202)  -15%             (101,703)  -27%                 17,501         -17%
Minority Interest (Loss)                               9,171    2%                (5,259)   -1%                 14,430        -274%
                                          -------------------         -------------------          --------------------

NET LOSS                                           $ (93,373)  -17%            $ (96,444)  -26%               $ 3,071           -3%
                                          ===================         ===================          ====================
</TABLE>

NET SALES

We generate three categories of revenues: tissue chip & kit product and
services. The net sales increased $167,279 to $543,541 for the nine months ended
September 30, 2007 from $376,262 for the nine months ended September 30, 2006.

Tissue Chip & Kit Product: The net sales increased $204,719 to $496,370 for the
nine months ended September 30, 2007 as compared to $291,651 for the nine months
ended September 30, 2006. The primary reason for the increase was due to the
sale of higher unit price tissue chip products in the first three quarters of
2007 as compared to the unit price of tissue chip products sold in the first
three quarters of 2006. The products sales in third quarter of 2007 also
contained the new kit products which generated net sales revenue of $ 4,066 in
third quarter of 2007.

Services: Fewer technical service orders were received during the nine months of
2007 as compared to 2006 resulting in a decrease in sales of $37,440 to $47,171
from $84,611 for the nine months ended September 30, 2007 as compared to
September 30, 2006. This decline is primarily attributable to increased
competition from larger better financed multinationals that can compete on the
basis of name recognition and pricing.

                                       13
<PAGE>

GROSS MARGIN

Gross margin as a percentage of sales decreased to 57% for the nine months ended
September 30, 2007 from 62% for the nine months ended September 30, 2006. Gross
profit for the nine months ended September 30, 2007 increased $75,629 to
$309,637 from $234,008 for the nine months ended September 30, 2006. The primary
reason for the increase in gross profit amount but the decrease in gross profit
margin is due to the increase in sales of tissue chip products with slightly
lower individual cost margin offset ]together with higher service costs and
lower gross profit margin services during the first three quarters of 2007 as
compared to the first three quarters of 2006.

OPERATING EXPENSES

Our operating expenses increased by $16,294 to $558,364 for the nine months
ended September 30, 2007 from $542,070 for the nine months ended September 30,
2006. This was primarily due to an increase in general and administrative
expenses of $12,472 to $470,032 for the nine months ended September 30, 2007
from $457,560 for the nine months ended September 30, 2006., and an increase in
selling and distribution expenses of $3,822 to $88,332 for the nine months ended
September 30, 2007 from $84,510 for the nine months ended September 30,
2006..The increase in selling expenses was primarily attributable to increased
advertising expenses. In addition, the increase in general and administrative
expenses were primarily attributable to increases of salaries and payroll taxes
in Cybrdi Maryland, increased R&D charges in Chaoying Biotech, and the increases
of the start-up cost for newly
 acquired subsidiary, SD Chaoying,

OTHER INCOME

Interest income decreased by $101,435 to $94,261 for the nine months ended
September 30, 2007 from $195,696 for the nine months ended September 30, 2006.
The interest income is primarily attributable to loans which we have made to
QuanYe. The decrease in interest income was primarily attributable to the
repayment of QuanYe loan in amount of $2,178,343 during the first three quarters
of year 2007.

Other income, net increased by $59,601 to $70,264 for the nine months ended
September 30, 2007 from $10,663 for the nine months ended September 30, 2006.
The increase was primarily attributable to a government grant received in the
amount of $59,903 during the nine months ended September 30, 2007.

INCOME TAXES

We have not recorded a provision for federal income tax for the nine months
ended September 30, 2007 and 2006, due to no taxable income. In accordance with
the relevant tax laws and regulations of the People's Republic of China,
Chaoying Biotech is entitled to full exemption from Corporation Income Tax
("CIT") for the first two years and a 50% reduction in CIT for the next three
years, commencing from the first profitable year after offsetting all tax losses
carried forward from the previous five years. As 2003 was Chaoying Biotech's
first profitable year, we begin to record 50% CIT provision from the first
quarter of 2005. The effective income tax rate is 7.5% for the nine months ended
September 30, 2007 and 2006.

LIQUIDITY AND CAPITAL RESOURCES

Operating working capital decreased by $2,599,520 from $4,258,523 as of December
31, 2006 to $1,659,003 as of September 30, 2007. The decrease was primarily due
to the purchase of the equity interest in SD Chaoying and the commencement of
construction in the aggregate amount of $3,188,626 offset by the repayment of
short-term loans in the amount of $2,178,343 and a loan acquired from an
affiliate in the amount of $266,923 as of September 30, 2007. Although we
incurred a net loss of $93,373 during the nine months ended September 30, 2007,
we generated net cash provided from operating activities for the nine months
ended September 30, 2007 in the amount of $165,653. The cash provided by
operating activities was primarily due to decreases in other receivable and


                                       14
<PAGE>

prepaid expenses of $80,786, and increased account payable and accrued expenses
in the amount of $18,837.

Net cash used in investing activities was $751,675, which consisted primarily of
net cash from investing activities of $2,178,343 from the repayment of the loan
to QuanYe, and a loan in the amount of $266,923 acquired from an affiliate
offset primarily by cash used in the purchase of intangible assets included land
use rights, and construction in progress in the amount of $3,123,458 and $37,525
in connection with the transaction with SD Chaoying during nine months ended
September 30, 2007, respectively.

Cash provided from financing activities in the amount of $423,754, consisted of
a $354,319 contribution from minority shareholders of SD Chaoying, and proceeds
from shareholders/officers of $257,473 offset by payments to
shareholders/officer of $188,038 during the nine months ended September 30,
2007.

On July 28, 2007, we acquired an 83.33 % equity ownership of SD Chaoying for a
purchase price of $1,983,078. As of September 30, 2007, SD Chaoying is still in
the development stage, and had invested an aggregate of $3,188,062 to acquire
land use rights, purchase equipments, and to commence construction of a culture
and entertainment facility, consisting primarily of spa activities, cosmetic
personal care, hotel,and casino. The construction project is anticipated to be
completed in December 2008 and is expected to cost approximately $9,300,000. In
order to finance this project, we anticipate borrowing $8.5 millions from
related parties and to utilize repayment of loan proceeds from Quan Ye. There
can be no assurance that we will be able to obtain the necessary financing for
the construction of the project.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this quarterly report on Form 10-QSB contain or may
contain forward-looking statements that are subject to known and unknown risks,
uncertainties and other factors which may cause actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. These
forward-looking statements were based on various factors and were derived
utilizing numerous assumptions and other factors that could cause our actual
results to differ materially from those in the forward-looking statements. These
factors include, but are not limited to, economic, political and market
conditions and fluctuations, government and industry regulation, interest rate
risk, U.S. and global competition, and other factors. Most of these factors are
difficult to predict accurately and are generally beyond our control. You should
consider the areas of risk described in connection with any forward-looking
statements that may be made herein. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of
this report. Readers should carefully review this quarterly report in its
entirety, including but not limited to our financial statements and the notes
thereto. Except for our ongoing obligations to disclose material information
under the Federal securities laws, we undertake no obligation to release
publicly any revisions to any forward-looking statements, to report events or to
report the occurrence of unanticipated events. For any forward-looking
statements contained in any document, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

RISK FACTORS

There had been no material changes in our risk factors from those disclosed in
our 2006 annual report on Form 10KSB.

You should consider each of the following risk factors and any other information
set forth in this Form 10-QSB and our other reports that we have filed with the
Securities and Exchange Commission ("SEC"), including our financial statements


                                       15
<PAGE>

and related notes, in evaluating our business and prospects. The risks and
uncertainties described below are not the only ones that impact on our
operations and business. Additional risks and uncertainties not presently known
to us, or that we currently consider immaterial, may also impair our business or
operations. If any of the following risks actually occur, our business and
financial condition, results or prospects could be harmed.

RISKS ASSOCIATED WITH OUR PROSPECTIVE BUSINESS AND OPERATIONS

We have a limited history with respect to the manufacture, sale and distribution
of TMAs. Medical technology is constantly evolving and there can be no assurance
that our TMAs will keep pace with medical breakthroughs. Our ability to achieve
and maintain profitability and positive cash flow over time will be dependent
upon, among other things, our ability to (i) continue to develop new TMA
products and market these products both in China and other developing countries
and (ii) our ability to evaluate the merits of pursuing the beauty supply
business and its success in developing franchise opportunities despite our lack
of prior experience.

OUR BUSINESS IS HEAVILY DEPENDENT ON THE ECONOMIC GROWTH OF CHINA

At the current time, our business is heavily dependent on the economy and the
developing middle and upper class in China. Should the country suffer an
economic downturn or should the government imposed restrictions on the growth of
private companies and the ability of a large consumer class to earn money in the
private sector our business will suffer. To the extent that any of the foregoing
should occur, our revenues will decline significantly.

WE MAY NOT BE ABLE TO SUPPORT OUR OPERATIONS THROUGH INTERNAL GROWTH

In order to fully implement our business plan, we may require additional
financing. Financing may be in the form of traditional bank financing or through
the sale of our common stock. There can be no assurance that we will be able to
secure adequate bank financing or if available, that it will be on terms
acceptable to us. If we attempt to sell shares of our common stock, existing
shareholders will face dilution and likely a reduction in the price of our
common stock. There are currently no financing arrangements in place.

OUR BUSINESS MAY BE AFFECTED BY UNEXPECTED CHANGES IN REGULATORY REQUIREMENTS IN
THE JURISDICTIONS IN WHICH WE OPERATE.

Development and distribution of our TMAs is subject to regulation both where we
manufacture and where we sell the products. We believe that we are currently in
compliance with applicable governmental rules and procedures. However, there can
be no assurance that changes in the regulatory environment will not make it
difficult for us to comply or result in a substantial increase in our operating
costs and a resulting decline in our margins.

THERE IS UNCERTAINTY AS TO OUR ABILITY TO CONTROL COSTS AND EXPENSES.

If our business grows, costs will increase. Management cannot accurately project
or give any assurance, with respect to its ability to control development and
operating costs and/or expenses in the future. Consequently, even if we are
successful in expanding our operations (of which there can be no assurance), our
management still may not be able to control costs and expenses adequately, and
therefore such expansion may result in operating losses.

WE FACE VARIOUS RISKS IN CONNECTION WITH OUR NEW BUSINESS.

As a result of our acquisition of an equity interest in SD Chaoying we will be
constructing a hotel and casino facility. We face significant risks in
constructing and operating the facility and entering into a new business in
which we do not have any prior experience. In addition, the hotel and casino
business is highly competitive and there can be no assurance that we will be
able to compete effectively. There can be no assurance that we will be able to
construct the facility in a cost efficient manner or that we will be able to
operate this business profitably.

                                       16
<PAGE>

COMPETITION

Our market is highly competitive and some of our competitors may have greater
resources than us. These competitors may be able to respond more quickly to new
or emerging technologies and changes in customer requirements and devote greater
resources to develop, promote and sell their products and services. If this
should occur, revenues may decline and we will likely lose market share.

IF WE DO NOT MANAGE OUR GROWTH, WE MAY NOT BE ABLE TO OPERATE OUR BUSINESS
EFFECTIVELY.

We expect significant expansion will be required to address potential growth in
our customer base, the breadth of our service offerings, and other
opportunities. This expansion could strain our management, operations, systems
and financial resources. To manage any future growth of our operations and
personnel, we must improve and effectively utilize operational, management,
marketing and financial systems and successfully recruit, hire, train and manage
personnel and maintain close coordination among our technical, finance,
marketing, sales and recruitment staffs. We also will need to manage an
increasing number of complex relationships with customers, strategic partners,
advertisers and other third parties. Our failure to manage growth could disrupt
our operations and ultimately prevent us from generating the revenue we expect.

UNANTICPATED OBSTACLES TO EXECUTION OF OUR BUSINESS PLAN.

Our business plans may change significantly. Many of our potential business
endeavors are capital intensive and may be subject to statutory or regulatory
requirements. Management believes that our chosen activities and strategies are
achievable in light of current economic and legal conditions with the skills,
background, and knowledge of our principals and advisors. Management reserves
the right to make significant modifications to our stated strategies depending
on future events.

CERTAIN POLITICAL AND ECONOMIC CONSIDERATIONS RELATING TO THE PRC COULD
ADVERSELY AFFECT OUR COMPANY.

The government of the People's Republic of China has welcomed foreign investment
and the expansion of business opportunities in the private sector. There can be
no assurance that this policy will continue or alternatively, that this policy
will not be modified to make it more restrictive to transfer funds from China to
the United States or any other country. Moreover, political instability could
adversely impact our ability to fully implement our business plan as political
instability would likely lead to a downturn in the Chinese economy.

CURRENCY EXCHANGE

Changes in the exchange rate of the Chinese yuan renminbi (CYN) may adversely
impact our profitability. If the CYN declines with respect to the U. S. dollar,
our profitability will be adversely affected.

RESEARCH AND DEVELOPMENT CAN BE COSTLY

Medical advances are taking place at a rapid pace. In order to stay competitive,
and bring state of the art TMAs to the market at competitive prices will require
us to continue to devote significant resources to research and development.
There can be no assurance that we will have sufficient cash flow to make this
commitment on a going forward basis.

                                       17
<PAGE>

RELIANCE ON CURRENT MANAGEMENT

We are reliant on our current management team to help us fully implement our
business plan. The loss of any of their services could have a material adverse
impact on the implementation of our business plan and our future growth. We do
not carry any type of key man insurance. During this past year, Dr. Liu resigned
as a director for personal reasons. Dr, Liu is in charge of our activities in
Maryland and will continue to run our US operations. We have not yet filled this
vacancy on our Board of Directors.

Our business may experience periods of rapid growth that will place significant
demands on our managerial, operational and financial resources. In order to
manage this potential growth, we must continue to improve and expand our
management, operational and financial systems and controls. We will need to
expand, train and manage our employee base. No assurances can be given that we
will be able to timely and effectively meet such demands.

WE MAY HAVE DIFFICULTY ATTRACTING TALENT IN FOREIGN COUNTRIES.

Our research and development program requires us to recruit highly skilled
personnel. There can be no assurance that we will be able to attract these
personnel for work either in the United States or China. If we cannot attract
skilled personnel, our operations will likely suffer and any competitive edge
that we have in the marketplace will quickly erode.

CORPORATE GOVERNANCE MATTERS

We have not voluntarily implemented various corporate governance measures in the
absence of which, shareholders may have more limited protections against
interested director transactions, conflicts of interest and similar matters.

Recent Federal legislation, including the Sarbanes-Oxley Act of 2002, has
resulted in the adoption of various corporate governance measures designed to
promote the integrity of the corporate management and the securities markets.

Some of these measures have been adopted in response to legal requirements.
Others have been adopted by companies in response to the requirements of
national securities exchanges, such as the NYSE or The Nasdaq Stock Market, on
which their securities are listed. Among the corporate governance measures that
are required under the rules of national securities exchanges and NASDAQ are
those that address board of directors' independence, audit committee oversight,
and the adoption of a code of ethics. While our board of directors has adopted a
Code of Ethics and Business Conduct, we have not yet adopted any of these other
corporate governance measures and, since our securities are not listed on a
national securities exchange or Nasdaq, we are not required to do so. It is
possible that if we were to adopt some or all of these corporate governance
measures, shareholders would benefit from somewhat greater assurances that
internal corporate decisions were being made by disinterested directors and that
policies had been implemented to define responsible conduct. For example, in the
absence of audit, nominating and compensation committees comprised of at least a
majority of independent directors, decisions concerning matters such as
compensation packages to our senior officers and recommendations for director
nominees may be made by a majority of directors who have an interest in the
outcome of the matters being decided. Prospective investors should bear in mind
our current lack of corporate governance measures in formulating their
investment decisions.

We may be exposed to potential risks relating to our internal controls over
financial reporting and our ability to have those controls attested to by our
independent auditors.

As directed by Section 404 of the Sarbanes-Oxley Act of 2002 ("SOX 404"), the
Securities and Exchange Commission adopted rules requiring public companies to
include a report of management on the company's internal controls over financial
reporting in their annual reports. In addition, the independent registered
public accounting firm auditing a company's financial statements must also
attest to and report on management's assessment of the effectiveness of our
internal controls over financial reporting as well as the operating
effectiveness of our internal controls. We are currently exempt from such
requirements through the year ended December 31, 2007.

                                       18
<PAGE>

While we expect to expend significant resources in developing the necessary
documentation and testing procedures required by SOX 404, there is a risk that
we will not comply with all of the requirements imposed thereby. At present,
there is no precedent available with which to measure compliance adequacy.
Accordingly, there can be no positive assurance that we will receive a positive
attestation from our independent auditors. In the event we identify significant
deficiencies or material weaknesses in our internal controls that we cannot
remediate in a timely manner or we are unable to receive a positive attestation
from our independent auditors with respect to our internal controls, investors
and others may lose confidence in the reliability of our financial statements
and our ability to obtain equity or debt financing could suffer.

RISKS RELATED TO OUR COMMON STOCK

WE DO NOT EXPECT TO PAY CASH DIVIDENDS IN THE FORESEEABLE FUTURE.

We have never paid cash dividends on our common stock and we have no plans to do
so in the foreseeable future. We intend to retain earnings, if any, to develop
and expand our business.

"PENNY STOCK" RULES MAY MAKE BUYING OR SELLING THE COMMON STOCK DIFFICULT A
SEVERELY LIMIT THEIR MARKET AND LIQUIDITY.

Trading in our common stock is subject to certain regulations adopted by the
SEC commonly known as the "Penny Stock Rules". Our common stock qualifies as a
penny stock and is covered by Section 15(g) of the Securities and Exchange Act
of 1934, as amended (the "1934 Act"), which imposes additional sales practice
requirements on broker/dealers who sell our common stock in the market. The
"Penny Stock" rules govern how broker/dealers can deal with their clients and
"penny stock". For sales of our common stock, the broker/dealer must make a
special suitability determination and receive from clients a written agreement
prior to making a sale. The additional burdens imposed upon broker/dealers by
the "penny stock" rules may discourage broker/dealers from effecting
transactions in our common stock, which could severely limit our market price
and liquidity. This could prevent investors from reselling our common stock and
may cause the price of the common stock to decline.

Although publicly traded, our common stock has substantially less liquidity than
the average trading market for a stock quoted on national exchanges, and our
price may fluctuate dramatically in the future.

Our Common Stock is currently quoted on the Pink Sheets. Our Common Stock was
previously listed for trading on the Over-the-Counter Electronic Bulletin Board.
The trading market in the common stock has substantially less liquidity than the
average trading market for companies quoted on national stock exchanges. A
public trading market having the desired characteristics of depth, liquidity and
orderliness depends on the presence in the marketplace of willing buyers and
sellers of our common stock at any given time. This presence depends on the
individual decisions of investors and general economic and market conditions
over which we have no control. Due to limited trading volume, the market price
of our common stock may fluctuate significantly in the future, and these
fluctuations may be unrelated to our performance. General market price declines
or overall market volatility in the future could adversely affect the price of
our common stock, and the current market price may not be indicative of future
market prices.

ITEM 4. CONTROLS AND PROCEDURES

An evaluation was carried out by our chief executive officer and treasurer of
the effectiveness of our disclosure controls and procedures (as defined in Rule
13a-15e or 15(d)-15(e) of the Securities Exchange Act of 1934) as of September
30, 2007. Based upon that evaluation, the chief executive officer and the
treasurer concluded that the design and operation of these disclosure controls
and procedures were effective after giving affect to the acquisition of Cybrdi,
Inc. by us and our obligations to comply with applicable accounting and
disclosure requirements.

                                       19
<PAGE>

PART II. OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

There is no material pending legal proceedings to which we are a party. We were
notified by a letter dated June 2, 2000 that we may have a potential liability
from waste disposal in the Casmalia Disposal Site at Santa Barbara County,
California. We were given a choice of either signing an agreement that would
toll the statute of limitations for eighteen (18) months in order to allow us to
resolve any liability with the government without incurring costs associated
with being named a defendant in a lawsuit, or becoming an immediate defendant in
a lawsuit. We signed the tolling agreement. On November 20, 2001, the tolling
agreement was extended for an additional 18 months. On May 20, 2003 the tolling
agreement was again extended for an additional 18 months and on November 24,
2004 the tolling agreement was again extended for additional 18 months. On June
29, 2004, we received a proposed settlement from the EPA in the amount of
$21,131. We are waiting for communication from the government concerning payment
of the proposed settlement. As of September 30, 2007, we have accrued a
sufficient amount to cover any potential liabilities from this matter.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES

None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5.  EXHIBITS

         10.1  Sales Agency Agreement between Shaanxi Chao Ying Biotech Co.,
               Ltd. and Biomax Co., Ltd.

         10.2  Equity Transfer Agreement dated July 26, 2007 by and between
               Shaanxi Chaoying Personal Care Group Co., Inc. and Shaanxi
               Chaoying Biotechnology Co., Ltd

         31.1  Rule 13(a)-14(a)/15(d)-14(a) Certification

         31.2  Rule 13(a)-14(a)/15(d)-14(a) Certification

         32.1  Certification Under Section 906 of the Sarbanes-Oxley Act fof
               2002

         32.2  Certification Under Section 906 of the Sarbanes-Oxley Act of 2002

(B)      REPORTS ON FORM 8-K:

         None.

                                       20
<PAGE>
                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                              CYBRDI, INC.


DATE:  December 21, 2007                      By /s/ Yanbiao Bai
                                                 ---------------
                                                 Yanbiao Bai
                                                 Chief Executive Officer
                                                 and President

                                       21